Skip to main content
. 2017 May 9;7(5):e015766. doi: 10.1136/bmjopen-2016-015766

Figure 1.

Figure 1

Schematic depiction of the trial design. Eligible participants are randomly assigned to a 24-week treatment regimen with either ipragliflozin (50 mg daily) or metformin (1000 mg daily, up to 1500 mg). DPP-4, dipeptidyl peptidase-4; HbA1c, glycosylated haemoglobin.